Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches. Issue 8 (3rd August 2021)

• Record Type: Journal Article
• Authors: Carnagarin, Revathy; Kiuchi, Marcio G.; Goh, Gerard; Adams, Leon; Cohen, Neale; Kavnoudias, Helen; Gan, Seng K.; Van Schie, Greg; Esler, Murray D.; Matthews, Vance B.; Schlaich, Markus P.
• Is Part Of: Journal of hypertension. Volume 39:Issue 8(2021)
• Page Start: 1478
• Page End: 1489
• Publication Date: 2021-08-03
• Subjects: hepatic denervation -- hypertension -- metabolic syndrome -- multiorgan denervation -- sympathetic nervous system; Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000002839
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Sympathetic overdrive plays a key role in the perturbation of cardiometabolic homeostasis. Diet-induced and exercise-induced weight loss remains a key strategy to combat metabolic disorders, but is often difficult to achieve. Current pharmacological approaches result in variable responses in different patient cohorts and long-term efficacy may be limited by medication intolerance and nonadherence. A clinical need exists for complementary therapies to curb the burden of cardiometabolic diseases. One such approach may include interventional sympathetic neuromodulation of organs relevant to cardiometabolic control. The experience from catheter-based renal denervation studies clearly demonstrates the feasibility, safety and efficacy of such an approach. In analogy, denervation of the common hepatic artery is now feasible in humans and may prove to be similarly useful in modulating sympathetic overdrive directed towards the liver, pancreas and duodenum. Such a targeted multiorgan neuromodulation strategy may beneficially influence multiple aspects of the cardiometabolic disease continuum offering a holistic approach.